Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Investing for the January Effect 2000 -- Ignore unavailable to you. Want to Upgrade?

To: Q. who wrote (49)	12/27/1999 11:35:00 AM
From: Richard Mazzarella	Respond to of 109

<<I bought some this a.m.>> PDX, me too. Sounds too good to be true, probably is. <VBG> However it's worth a bet.

To: Q. who wrote (49)	12/27/1999 7:51:00 PM
From: Michael Dunn	Read Replies (1) \| Respond to of 109

I've enjoyed the thread and after some DD picked up some EBSC. My top January effect pick is CRPB (which is also my top value/cyclical recovery pick for 2000). Cerprobe (CRPB) produces probe cards used to interface probers (made by EGLS among others) to chips. These probers along with the probe card, which is uniquely made for each chip type, test chips at the tail end of the semiconductor IC manufacturing process (just prior to packaging). It is currently trading at $7 which is close to book value, PSR=1, ~$2.00/share in cash. CRPB has grown quickly over the years through market share gain and acquisitions. Being an unnoticed small cap with a product cycle that, according to the CEO, lags semiconductor equipment cycles by 6 months has resulted in an incredible resonable valuation for a semiconductor equipment company. I believe they fit your Jan effect criteria. They are a small cap, with low institutional holdings, at the low end of their 99 price range, and with 70k shares of insider buys in the last 6 months (an no sales) as a result they are my top January effect pick and my top 2000 value pick. Their backlogs are reportedly strong. I'm looking for strong double digit revenue and earnings growth in the next 4 quarters. To my knowledge they have no competitors except with semiconductor manufacturers that make their probe cards in house rather than outsourcing. EGLS proberx requires a probe card for every different chip it tests. As a result I consider EGLS, whose sales and stock price has ramped quickly over the past several months, to be a forward indicator for CRPB. Best wishes, Mike